McCloskey, E V; Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK. e.v.mccloskey@sheffield.ac.uk ; Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. e.v.mccloskey@sheffield.ac.uk
Chotiyarnwong, P; Mellanby Centre for Musculoskeletal Research, MRC Versus Arthritis Centre for Integrated Research in Musculoskeletal Ageing, Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK ; Department of Orthopaedic Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Harvey, Nick ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
Lorentzon, M; University of Gothenburg, Gothenburg, Sweden ; Australian Catholic University, Melbourne, Australia
Kanis, J A; Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK ; Australian Catholic University, Melbourne, Australia
International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
Bruyère, Olivier ; Université de Liège - ULiège > Unité de recherche Santé publique, épidémiologie et économie de la santé (URSAPES)
Language :
English
Title :
Population screening for fracture risk in postmenopausal women - a logical step in reducing the osteoporotic fracture burden?
Publication date :
28 June 2022
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science and Business Media Deutschland GmbH, England
E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work.D.P-A. reports institutional receipt of speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier, all outside of the submitted work.B.A. reports grants and personal fees from UCB, personal fees from Amgen, grants from Novartis, grants and personal fees from Pharma-cosmos, grants and personal fees from Kyowa Kirin, personal fees for Gedeon Richter outside the submitted work. BA also serves on the NovoNordisk Foundation Grants Committee on Endocrinology and Metabolism.E.V.M reports consultant/advisor fees, speaker honoraria and or, research funding from AgNovos, Amgen, Consilient Healthcare, Fresenius Kabi, Gedeon Richter, Internis, Lilly, Novartis, ObsEva, Synexus, and UCB, all outside the submitted work.
British Orthopaedic Association (2007) The care of patients with fragility fracture. Available at: http://www.boaacuk/Publications/Documents/TheCareofPatientswithFragilityFracturepdf. Accessed 18 Aug 2021
Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care 53:686–691
Chesser TJS, Inman D, Johansen A et al (2020) Hip fracture systems-European experience. OTA Int 3:e050
Tarrrant SM, Ajgaonkar A, Babhulkar S et al (2020) Hip fracture care and national systems: Australia and Asia. OTA Int 3:e058
Marsh D, Akesson K, Beaton DE et al (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065
Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, Group IOFFW (2013) Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152
Majumdar SR, McAlister FA, Johnson JA et al (2018) Comparing strategies targeting osteoporosis to prevent fractures after an upper extremity fracture (C-STOP Trial): a randomized controlled trial. J Bone Miner Res 33:2114–2121
Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, Hanley DA, Morrish DW, Maksymowych WP, Rowe BH (2008) Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ 178:569–575
Majumdar SR, Rowe BH, Folk D et al (2004) A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 141:366–373
Axelsson KF, Johansson H, Lundh D, Moller M, Lorentzon M (2020) Association between recurrent fracture risk and implementation of fracture liaison services in four swedish hospitals: a cohort study. J Bone Miner Res 35:1216–1223
Javaid MK (2021) Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures. Aging Clin Exp Res 33:2061–2067
McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32:251–259
Skjodt MK, Ernst MT, Khalid S et al (2021) The treatment gap after major osteoporotic fractures in Denmark 2005–2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. Osteoporos Int 32:1961–1971
Galli S, Weiss D, Beck A, Scerpella T (2021) Osteoporosis care gap after hip fracture - worse with low healthcare access and quality. J Clin Densitom S1094–6950(21)00076–7. https://doi.org/10.1016/j.jocd.2021.09.002
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M (2021) Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan. Arch Osteoporos 16:131
Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034
UK National Screening Committee (2019) Screening for Osteoporosis in Postmenopausal Women 08 November 2019. https://view-health-screening-recommendations.service.gov.uk/osteoporosis/. Accessed 18 Aug 2021
EUnetHTA OTCA19 Assessment Team (2019) Screening for osteoporosis in the general population. Collaborative Assessment. Diemen (The Netherlands): EUnetHTA; 2019. Report No.: OTCA19. Available from https://www.eunethta.eu. Accessed 18 Aug 2021
Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251–257
Chotiyarnwong P, McCloskey EV, Harvey NC et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Arch Osteoporos (submitted)
Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. World Health Organization https://apps.who.int/iris/handle/10665/37650. Accessed 18 Aug 2021
Shepstone L, Fordham R, Lenaghan E et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int 23:2507–2515
Shepstone L, Lenaghan E, Cooper C et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741–747
McCloskey E, Johansson H, Harvey NC et al (2018) Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res 33:1020–1026
Parsons CM, Harvey N, Shepstone L et al (2019) Systematic screening using FRAX((R)) leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int
Turner DA, Khioe RFS, Shepstone L et al (2018) The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res 33:845–851
Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256
Leslie WD, Morin S (2011) Fracture burden in relation to low bone mineral density and FRAX((R)) probability. J Clin Densitom 14:279–285
Svedbom A, Ivergard M, Hernlund E, Rizzoli R, Kanis JA (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9:187
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82
Borgstrom F, Karlsson L, Ortsater G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427
WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva
US Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154:356–364
US Preventive Services Task Force (2018) Screening for osteoporosis to prevent fractures. US preventive services task force recommendation statement. JAMA 319(24):2521–2531. 10.1001/jama20187498 DOI: 10.1001/jama20187498
Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, Advisory Board of the National Osteoporosis Guideline G (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25
National Institute for Health and Care Excellence (2012) NICE Clinical Guideline 146. Osteoporosis: assessing the risk of fragility fracture. https://www.nice.org.uk/guidance/cg146. Accessed 18 Aug 2021
Leslie WD, Lix LM (2014) Comparison between various fracture risk assessment tools. Osteoporos Int 25:1–21
Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis 74:1958–1967
Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC (2018) Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force. JAMA 319:2532–2551
Nayak S, Edwards DL, Saleh AA, Greenspan SL (2015) Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26:1543–1554
Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431
Dagan N, Cohen-Stavi C, Leventer-Roberts M, Balicer RD (2017) External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study. BMJ 356:i6755
Cummings SR, Nevitt MC (1989) A hypothesis: the causes of hip fractures. J Gerontol 44:M107-111
Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012(9):CD007146. https://doi.org/10.1002/14651858.CD007146.pub3
Bhasin S, Gill TM, Reuben DB et al (2020) A randomized trial of a multifactorial strategy to prevent serious fall injuries. N Engl J Med 383:129–140
Lamb SE, Bruce J, Hossain A et al (2020) Screening and intervention to prevent falls and fractures in older people. N Engl J Med 383:1848–1859
Guirguis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL (2018) Interventions to prevent falls in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA 319:1705–1716
Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348:1535–1541
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427
Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202
Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M,.. Reginster J (2019) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1–12. https://doi.org/10.1007/s00198-019-05176-3
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
Cauley JA, Robbins J, Chen Z et al (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738
McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135–141
McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy–additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture Prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407–2416
Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567–578
Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993–2000
Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361
Torgerson DJ, Thomas RE, Campbell MK, Reid DM (1997) Randomized trial of osteoporosis screening. Use of hormone replacement therapy and quality-of-life results. Arch Intern Med 157:2121–2125
Barr RJ, Stewart A, Torgerson DJ, Reid DM (2010) Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int 21:561–568
Owen L, Pennington B, Fischer A, Jeong K (2017) The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016. J Public Health 40(3):557–566. 10.1093/pubmed/fdx119 DOI: 10.1093/pubmed/fdx119
Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N (2013) Cost effectiveness of the NHS breast screening programme: life table model. BMJ 346:f2618
Lee D, Muston D, Sweet A, Cunningham C, Slater A, Lock K (2010) Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years. Appl Health Econ Health Policy 8(13):141–154
